Do antipsychotics work in people with schizophrenia? A review of outcomes and effect sizes
CNS Spectrums · 2025 · 30 (1)
DOI: 10.1017/s1092852925100461 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift CNS Spectrums, online erschienen am 31.07.2025. Verfasst von Christoph U Correll. Beteiligte Einrichtung: Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA. Hauptthemen laut MEDLINE: Schizophrenia, Antipsychotic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The origins and treatment-target-related mechanisms of schizophrenia remain to be fully understood. Pharmacological and non-pharmacological treatments require expansion and improvements to meet peoples’ needs and goals. Nevertheless, antipsychotics are a cornerstone when managing schizophrenia, being essential for reducing symptom severity, preventing relapse, improving long-term functional outcomes, and reducing premature mortality risk.
Methods
This narrative review synthesizes key evidence on the efficacy and risks associated with antipsychotic medications. The concept of effect sizes is introduced, allowing to compare antipsychotics across trials with different rating instruments and across different conditions.
Results
The available evidence in schizophrenia and comparison with medications used for medical conditions counters the sometimes-voiced criticism that antipsychotics “do not work.” Instead, for a substantial group of people with schizophrenia, positive psychotic symptoms and global psychopathology improve witha small-medium effect size of about 0.4 versus placebo. These results are comparable to median effect sizes across commonly used medications for somatic disorders. When patients with initial response are continued on antipsychotics, the effect size increases to 0.9 for relapse prevention, translating into a number needed to treat (NNT) of about 3 to prevent one more relapse versus no treatment. This NNT is 10–20 times higher than that for the prevention of poor outcomes in some common medical conditions.
Conclusions
Despite general efficacy and effectiveness of antipsychotics for schizophrenia, further development is needed regarding preventive interventions and medications with mechanisms other than postsynaptic dopamine receptor blockade, with broader efficacy for positive, negative, cognitive, suicidality, and/or reward dysregulation symptomatology, and the identification of illness mechanism/biomarker-targeting treatments to enhance treatment personalization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA.
- Department of Psychiatry and Molecular Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA.
- Department of Child and Adolescent Psychiatry, Charité-Universitätsmedizin Berlin, Berlin, Germany.
- German Center for Mental Health (DZPG), Partner Site Berlin, Berlin, Germany.
- Einstein Center for Population Diversity (ECPD), Berlin, Germany.
ORCID-Profile: Christoph U Correll
Zitieren
APA
Correll, C. U. (2025). Do antipsychotics work in people with schizophrenia? A review of outcomes and effect sizes. CNS Spectrums, 30(1). https://doi.org/10.1017/s1092852925100461
Vancouver
Correll CU. Do antipsychotics work in people with schizophrenia? A review of outcomes and effect sizes. CNS Spectrums. 2025;30(1). doi:10.1017/s1092852925100461
BibTeX
@article{Correll2025,
author = {Correll, Christoph U},
title = {Do antipsychotics work in people with schizophrenia? A review of outcomes and effect sizes},
journal = {CNS Spectrums},
year = {2025},
volume = {30},
number = {1},
doi = {10.1017/s1092852925100461}
}
EUVIMED